ReviewTrends in pharmacological sciences2010
Molecular basis of pharmacotherapies for cognition in Down syndrome.
Review in Trends in pharmacological sciences, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 79 citations in OpenAlex.
- Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation.American journal of medical genetics. Part A · 2011Trial
- Current insights and prospects for the pathogenesis and treatment of clinical manifestations associated with Down syndrome through neurotransmitter, inflammatory, and oxidative stress pathways.Frontiers in pharmacology · 2025Review
- Embryonic organizer formation disorder leads to multiorgan dysplasia in Down syndrome.Cell death & disease · 2022Article
- The correlation between vitamin D and levels of IFN-γ, NF-κB, thyroid antibodies in down syndrome: study in Indonesian children.Acta bio-medica : Atenei Parmensis · 2022Article
- Long noncoding RNAGenes & diseases · 2022Review
- Altered patterning of trisomy 21 interneuron progenitors.Stem cell reports · 2022Article
- Aging with Down Syndrome-Where Are We Now and Where Are We Going?Journal of clinical medicine · 2021Review
- Identification of a thymus microRNA‑mRNA regulatory network in Down syndrome.Molecular medicine reports · 2019Article
- Timing of Treatment with the Flavonoid 7,8-DHF Critically Impacts on Its Effects on Learning and Memory in the Ts65Dn Mouse.Antioxidants (Basel, Switzerland) · 2019Article
- In silico identification of critical proteins associated with learning process and immune system for Down syndrome.PloS one · 2019Article
- Human Models Are Needed for Studying Human Neurodevelopmental Disorders.American journal of human genetics · 2018Review
- Trisomy silencing by XIST normalizes Down syndrome cell pathogenesis demonstrated for hematopoietic defects in vitro.Nature communications · 2018Article
- On the Design of Broad-Based Neuropsychological Test Batteries to Assess the Cognitive Abilities of Individuals with Down Syndrome in the Context of Clinical Trials.Brain sciences · 2018Review
- Bi-stream CNN Down Syndrome screening model based on genotyping array.BMC medical genomics · 2018Article
- Proteomic analysis of six- and twelve-month hippocampus and cerebellum in a murine Down syndrome model.Neurobiology of aging · 2018Article
- Long noncoding RNA and its contribution to autism spectrum disorders.CNS neuroscience & therapeutics · 2017Review
- The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome.Frontiers in cellular neuroscience · 2017Review
- Disinhibition, an emerging pharmacology of learning and memory.F1000Research · 2017Review
- Integrated miRNA and mRNA expression profiling in fetal hippocampus with Down syndrome.Journal of biomedical science · 2016Article
- Down Syndrome: Current Status, Challenges and Future Perspectives.International journal of molecular and cellular medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Intellectual disability in Down syndrome (DS) ranges from low normal to severely impaired and has a significant impact on the quality-of-life of the individuals affected and their families. Because the incidence of DS remains at approximately 1 in 700 live births and the lifespan is now >50 years, development of pharmacotherapies for cognitive deficits is an important goal. DS is due to an extra copy of human chromosome 21 and has often been considered too complex a genetic abnormality to be amenable to intervention. However, recent successes in rescuing learning/memory impairments in a mouse model of DS suggest that this negative outlook may not be justified. In this contribution, we first review the DS phenotype, chromosome 21 gene content and mouse models. We then discuss recent successes and the remaining challenges in the identification of targets for and preclinical evaluation of potential therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.